The decision to reimburse APRETUDE through the NIHB Program will have a meaningful impact on HIV prevention efforts for eligible First Nations and Inuit people who are at-risk of HIV and could ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi ...

The Trump administration this week decimated HIV prevention programs across government health agencies after terminating ...

In part 1 of this interview with Katrina Ortblad, ScD, MPH, she addressed bridging gaps in HIV care with pharmacy-based ...

House Bill 2769, titled Life or Health Insurances; Unfair Discrimination, Pre-Exposure Prophylaxis for Prevention of HIV, was ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis (PrEP) medication. A once-a-year prophylactic injection to protect ...

At the moment, the greatest impact is on prevention, as only 11 of the 30 promoters who supported doctors in initiating PrEP for key population users in the VICITS clinics have been rehired. Therefore ...

Over the years, the network had evolved to study other health issues facing youth beyond HIV, including STIs, substance use ...

Wisconsin could be hit hard if the Trump administration follows through on eliminating the CDC's HIV prevention division.

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...